Patents by Inventor Morteza Asgari

Morteza Asgari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intracellular antigens for identifying fetal cells in maternal blood
    Patent number: 5861253
    Abstract: Fetal cells may be obtained from amniocentesis, chorionic villus sampling, percutaneous umbilical cord sampling or in vitro fertilization embryos or products of conception, but are preferably from maternal peripheral blood. Fetal cells may be enriched by density gradient centrifugation. Fetal cells may also be enriched by removing maternal cells with an antibody to a cell surface antigen, e.g. anti-CD45, either immobilized or by fluorescence-activated cell sorting. Fetal cells are also distinguishable from maternal cells by staining, e.g. with a labeled antibody to cytokeratin or to fetal hemoglobin, or for fetal hemoglobin by hematoxylin/eosin, or by in situ hybridization to detect one or more fetal mRNAs, e.g., of fetal hemoglobin or fetoprotein. Amplification may be used in conjunction with the in situ hybridization. Fetal cells circulating in maternal blood may be separated by flow cytometry, sorting on their intrinsic light scattering properties.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: January 19, 1999
    Assignee: Aprogenex, Inc.
    Inventors: Morteza Asgari, Mark Blick, Joel Bresser, Michael Lee Cubbage, Nagindra Prashad
  • Amplification of mRNA for distinguishing fetal cells in maternal blood
    Patent number: 5858649
    Abstract: Fetal cells may be obtained from amniocentesis, chorionic villus sampling, percutaneous umbilical cord sampling or in vitro fertilization embryos or products of conception, but are preferably from maternal peripheral blood. Fetal cells may be enriched by density gradient centrifugation. Fetal cells may also be enriched by removing maternal cells with an antibody to a cell surface antigen, e.g. anti-CD45, either immobilized or by fluorescence-activated cell sorting. Fetal cells are also distinguishable from maternal cells by staining, e.g. with a labeled antibody to cytokeratin or to fetal hemoglobin, or for fetal hemoglobin by hematoxylin/eosin, or by in situ hybridization to detect one or more fetal mRNAs, e.g., of fetal hemoglobin or fetoprotein. Amplification may be used in conjunction with the in situ hybridization. Fetal cells circulating in maternal blood may be separated by flow cytometry, sorting on their intrinsic light scattering properties.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: January 12, 1999
    Assignee: Aprogenex, Inc.
    Inventors: Morteza Asgari, Mark Blick, Joel Bresser, Michael Lee Cubbage, Nagindra Prashad
  • Enriching and identifying fetal cells in maternal blood for in situ hybridization on a solid surface
    Patent number: 5766843
    Abstract: Fetal cells may be obtained from amniocentesis, chorionic villus sampling, percutaneous umbilical cord sampling or in vitro fertilization embryos or products of conception, but are preferably from maternal peripheral blood. Fetal cells may be enriched by density gradient centrifugation. Fetal cells may also be enriched by removing maternal cells with an antibody to a cell surface antigen, e.g. anti-CD45, either immobilized or by fluorescence-activated cell sorting. Fetal cells are also distinguishable from maternal cells by staining, e.g. with a labeled antibody to cytokeratin or to fetal hemoglobin, or for fetal hemoglobin by hematoxylin/eosin, or by in situ hybridization to detect one or more fetal mRNAs, e.g., of fetal hemoglobin or fetoprotein. Amplification may be used in conjunction with the in situ hybridization. Fetal cells circulating in maternal blood may be separated by flow cytometry, sorting on their intrinsic light scattering properties.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: June 16, 1998
    Assignee: Aprogenex, Inc.
    Inventors: Morteza Asgari, Mark Blick, Joel Bresser, Michael Lee Cubbage, Nagindra Prashad
  • Enriching and identifying fetal cells in maternal blood for in situ hybridization
    Patent number: 5629147
    Abstract: Fetal cells may be obtained from amniocentesis, chorionic villus sampling, percutaneous umbilical cord sampling or in vitro fertilization embryos or products of conception, but are preferably from maternal peripheral blood. Fetal cells may be enriched by density gradient centrifugation. Fetal cells may also be enriched by removing maternal cells with an antibody to a cell surface antigen, e.g. anti-CD45, either immobilized or by fluorescence-activated cell sorting. Fetal cells are also distinguishable from maternal cells by staining, e.g. with a labeled antibody to cytokeratin or to fetal hemoglobin, or for fetal hemoglobin by hematoxylin/eosin, or by in situ hybridization to detect one or more fetal mRNAs, e.g., of fetal hemoglobin or fetoprotein. Amplification may be used in conjunction with the in situ hybridization. Fetal cells circulating in maternal blood may be separated by flow cytometry, sorting on their intrinsic light scattering properties.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: May 13, 1997
    Assignee: Aprogenex, Inc.
    Inventors: Morteza Asgari, Mark Blick, Joel Bresser, Michael L. Cubbage, Nagindra Prashad